- Home
- JDZG vs ITRM Comparison
JDZG vs ITRM Comparison
Compare JDZG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JDZG
- ITRM
- Stock Information
- Founded
- JDZG 2020
- ITRM 2015
- Country
- JDZG China
- ITRM Ireland
- Employees
- JDZG N/A
- ITRM N/A
- Industry
- JDZG Other Consumer Services
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- JDZG Real Estate
- ITRM Health Care
- Exchange
- JDZG Nasdaq
- ITRM Nasdaq
- Market Cap
- JDZG N/A
- ITRM 37.7M
- IPO Year
- JDZG 2024
- ITRM 2018
- Fundamental
- Price
- JDZG $0.50
- ITRM $1.08
- Analyst Decision
- JDZG
- ITRM Strong Buy
- Analyst Count
- JDZG 0
- ITRM 1
- Target Price
- JDZG N/A
- ITRM $5.00
- AVG Volume (30 Days)
- JDZG 374.0K
- ITRM 300.3K
- Earning Date
- JDZG 05-20-2025
- ITRM 05-12-2025
- Dividend Yield
- JDZG N/A
- ITRM N/A
- EPS Growth
- JDZG N/A
- ITRM N/A
- EPS
- JDZG 0.06
- ITRM N/A
- Revenue
- JDZG $2,334,771.00
- ITRM N/A
- Revenue This Year
- JDZG N/A
- ITRM N/A
- Revenue Next Year
- JDZG N/A
- ITRM $150.10
- P/E Ratio
- JDZG $8.34
- ITRM N/A
- Revenue Growth
- JDZG 52.08
- ITRM N/A
- 52 Week Low
- JDZG $0.45
- ITRM $0.81
- 52 Week High
- JDZG $15.08
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- JDZG N/A
- ITRM 32.84
- Support Level
- JDZG N/A
- ITRM $1.05
- Resistance Level
- JDZG N/A
- ITRM $1.16
- Average True Range (ATR)
- JDZG 0.00
- ITRM 0.08
- MACD
- JDZG 0.00
- ITRM -0.00
- Stochastic Oscillator
- JDZG 0.00
- ITRM 13.04
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.